Daiichi Sankyo & AstraZeneca's datopotamab deruxtecan recommended for approval in EU to treat patients with previously ...
Datopotamab deruxtecan (Dato-DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast …